All articles by Phillip Broadwith – Page 9
-
BusinessIneos lands first US shale gas in UK
Massive tankers create a ‘virtual pipeline’ bringing feedstock to replace dwindling domestic supplies
-
BusinessJ&J to buy Abbott Medical Optics
Deal adds laser surgery and cataract lens replacements to J&J’s eyecare business
-
BusinessDanaher boosts diagnostics with Cepheid buyout
$4bn deal strengthens Danaher’s life sciences portfolio
-
-
BusinessJoined-up thinking
The rift between contract medicinal chemistry and chemical development needs to be bridged
-
BusinessPfizer to buy Astrazeneca’s antibiotics
Deal tops up Pfizer’s late-stage development pipeline, but AZ will retain biological programmes
-
OpinionHow do companies deal with political shifts?
Political instability hits small companies hardest
-
BusinessJob cuts at Takeda, Boehringer and Arena
Hundreds of positions eliminated as companies re-evaluate R&D
-
BusinessFibrant to quit US operations
Caprolactam supplier will shed hundreds of jobs, while operations in Europe and China continue
-
BusinessArkema boosts Bostik adhesives
New adhesives plant in Sweden and acquisition of Dutch firm Den Braven
-
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
-
OpinionTime for better incentives to keep drug costs low
Getting outraged at drug price hikes is all very well, but we need more constructive options
-
-
BusinessHenkel to buy detergent maker Sun Products
€3.2bn deal boosts Henkel’s position in North American laundry care market
-
BusinessAstraZeneca licenses skin drugs to Leo
Offloading psoriasis and dermatitis antibodies continues AZ’s plan to refocus on fewer therapy areas
-
BusinessNovartis partners with Xencor for cancer antibodies
Deal deepens Novartis’s focus on immuno-oncology
-
Business
Teva sells off products in preparation for Allergan merger
Generics deals with Impax, Dr Reddy’s and Sagent aimed at satisfying competition authorities
-
BusinessBASF boosts coatings with Chemetall buyout
$3.2bn purchase from Albemarle continues BASF’s efforts to expand and refocus its coatings division
-
Business
Merck & Co to buy Afferent for neurology drugs
Deal worth up to $1.25bn includes drug candidate for chronic coughs
-
BusinessJ&J to buy Vogue for haircare range
$3.3bn deal expands Johnson & Johnson’s consumer products segment